Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEA CAR-T cells · 2 trials · 9 indications
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Dose-limiting toxicity after cell infusion
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Dose-limiting toxicity after cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg |
| intraperitoneal injection of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | EXPERIMENTAL | Intraperitoneal infusion of FAST CEA-targeted CAR-T cells by 4 dose levels |
| Name | Type | Description |
|---|---|---|
| CEA CAR-T cells | BIOLOGICAL | After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | BIOLOGICAL | Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion. |
Inclusion Criteria: 1. Age ≥18 years old, male or female; 2. Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer; 3. After receiving at least second-line standard treatment failure...
Top 20 of 77 competitors
CEA CAR-T cells is an investigational chimeric antigen receptor T-cell therapy being studied for the treatment of CEA-positive advanced malignant solid tumors, including gastric cancer and colorectal cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CEA CAR-T cells is being developed by Precision BioSciences, Inc., a biotechnology company listed on NASDAQ under the ticker symbol DTIL. The therapy is in Phase 1 clinical trials for the treatment of CEA-positive solid tumors.
CEA CAR-T cells is in Phase 1 clinical development. It is an investigational therapy and has not received regulatory approval. Two Phase 1 trials are currently recruiting participants to evaluate its safety and efficacy in patients with CEA-positive advanced solid tumors.
CEA CAR-T cells is being evaluated in two Phase 1 clinical trials. The first, NCT05396300, is studying the therapy in CEA-positive advanced malignant solid tumors, including colorectal and gastric cancer, with an enrollment of 110 participants. The second, NCT06010862, is investigating it in CEA-positive advanced or metastatic solid tumors, including gastric, colon, and other cancers, with 36 participants.
Yes, CEA CAR-T cells is also referred to as CEA-targeted CAR-T in clinical trial documentation. The trials NCT05396300 and NCT06010862 both describe the therapy as CEA-targeted CAR-T, indicating that the names are used interchangeably for the same investigational cell therapy.